

Spearman's rank-order correlation to compare hospitals on these metrics and their associated rankings.

**Results.** At the hospital-level, the median ASI/DOT, ASI/1,000 DP and DOT/1,000 DP were 5.4 (interquartile range: 5.2-5.8), 2,332.7 (1,941.8-2,796.2) and 443.5 (362.5-512.2), respectively. There was a strong correlation between the ASI/1,000 DP and DOT/1,000 DP metrics [Spearman's correlation test:  $r=0.97$  ( $p < 0.01$ )] but only a weak and insignificant correlation between ASI/DOT and DOT/1,000 DP [ $r=0.17$  ( $p=0.06$ ), Figure 1]. Twenty (16.1%) hospitals showed a difference of 10% or more in their ranking for ASI/1,000 DP compared to their ranking for DOT/1,000 DP. The range of ranking difference was from -17.7% to 21.0% (Figure 2a and b).

Figure 1. Distribution of the Antibiotic Spectrum Index / Day of Therapy by Days of Therapy / 1000 Days Present for 124 Acute-Care VHA Hospitals during 2018. Black line: Median values of DOT/1,000 DP and ASI/DOT, respectively.





Figure 2. (a) Distribution of the rankings in DOT/1,000 DP and ASI/1,000 DP. Blue line: the position of same ranking between ASI/1,000 DP and DOT/1,000 DP. (b) Distribution of the differences in each hospital's ranking for DOT/1,000 DP and ASI/1,000 DP



**Conclusion.** Our findings suggest that hospitals using fewer days of antibiotic therapy did not necessarily use narrower-spectrum antibiotics. ASI/1,000 DP, as a combined measure of antibiotic consumption quantity and average spectrum, provided a different view of hospital performance than DOT/1,000 DP alone. Future work is needed to define how this new metric relates to the quality of antibiotic use.

**Disclosures.** All Authors: No reported disclosures

### 103. Expansion of an Antimicrobial Stewardship Program Through Implementation of a Discharge Verification Queue

Ellen C. Rubin, PharmD, BCPS<sup>1</sup>; Alison L. Blackman, PharmD, BCIDP<sup>1</sup>; Eleanor K. Broadbent, PharmD<sup>1</sup>; David Wang, PharmD<sup>1</sup>; Ilda Plasari, PharmD<sup>1</sup>; Pawlose Ketema, PharmD<sup>1</sup>; Karrine Brade, PharmD<sup>1</sup>; Tamar F. Barlam, MD, MSc<sup>1</sup>; <sup>1</sup>Boston Medical Center, South Boston, Massachusetts

**Session:** P-07. Antimicrobial Stewardship: Program Development and Implementation

**Background.** Antimicrobial stewardship programs (ASPs) have traditionally focused interventions on inpatient care to improve antibiotic prescribing. Support of effective interventions for ASPs targeting antibiotic prescriptions at hospital discharge is emerging. Our objective was to expand stewardship services into the outpatient setting through implementation of a process by the antimicrobial stewardship team (AST) to verify antimicrobials prescribed at discharge.

**Methods.** This quality improvement initiative incorporated a discharge order verification queue managed by AST pharmacists to review electronically prescribed antimicrobials Monday through Friday, from 8:00 am to 4:00 pm. The queue was piloted Sep 2020 and expanded hospital-wide Feb 2021. Patients < 18 years old and those with observation or emergency department status were excluded. The AST pharmacist reviewed discharge prescriptions for appropriateness, intervened directly with prescribers, and either rejected or verified prescriptions prior to transmission to outpatient pharmacies. Complicated cases were reviewed with the AST physician to evaluate intervention appropriateness. Interventions were categorized as either dose adjustment, duration, escalation or de-escalation, discontinuation, or safety monitoring.

**Results.** A total of 602 prescriptions were reviewed between Sep 2020 and Apr 2021. An AST pharmacist intervened on 28% (171/602) of prescriptions. The most common intervention types were duration (41%, 70/171), discontinuation (18%, 31/171), and dose adjustment (17%, 30/171). The most common indications in which the duration was shortened was community acquired pneumonia (26%, 18/70), skin and soft tissue infection (21%, 15/70), and urinary tract infection (17%, 12/70). The most common antibiotics recommended for discontinuation were cephalexin (32%, 10/31) and trimethoprim-sulfamethoxazole (10%, 3/31). The overall intervention acceptance rate was 78%.

**Conclusion.** An AST pharmacist review of antimicrobial prescriptions at discharge improved appropriate prescribing. The discharge queue serves as an effective stewardship strategy for inpatient ASPs to expand into the outpatient setting.

**Disclosures.** All Authors: No reported disclosures

### 104. Improving Efficiency of Antimicrobial Stewardship Reviews Using Artificial Intelligence Modelling

Si Lin Sarah Tang, BSc Pharm (Hons), MSc<sup>1</sup>; Winnie Lee, MSc<sup>1</sup>; Yiling Chong, MTech<sup>2</sup>; Akshay Saigal, B.Eng (Electronics)<sup>2</sup>; Peijun Yvonne Zhou, BSc Pharm (Hons), MSc<sup>1</sup>; Kai Chee Hung, BSc (Pharmacy)<sup>1</sup>; Lun Yi Tan, BSc<sup>1</sup>; Shimin Jasmine Chung, M.B.B.S, BSc, MRCP<sup>1</sup>; Lay Hoon Andrea Kwa, PharmD<sup>1</sup>; <sup>1</sup>Singapore General Hospital, Singapore, Not Applicable, Singapore; <sup>2</sup>DXC Technology, Singapore, Not Applicable, Singapore


**Session:** P-07. Antimicrobial Stewardship: Program Development and Implementation

**Background.** Antimicrobial stewardship programs (ASP) in hospitals improve antibiotic prescribing, slow antimicrobial resistance, reduce hospitalisation duration, mortality and readmission rates, and save costs. However, the strategy of prospective audit and feedback is laborious. In Singapore General Hospital (SGH), 10 reviews are required to identify 2 inappropriate cases. Limited manpower constraints ASP audits to only about 30% of antibiotics prescribed. This proof-of-concept study explored the feasibility of developing a predictive model to prioritise inappropriate antibiotic prescriptions for ASP review.

**Methods.** ASP-audited adult pneumonia patients from January 2016 to December 2018 in SGH were included. Patient data e.g., demographics, allergies, past medical history, and relevant laboratory investigations at each antibiotic use episode were extracted from electronic medical records and re-assembled through linking for analysis. Ground truth for model training was based on ASP-defined appropriateness for each encounter. The dataset was split into 80% and 20% for training and testing respectively. Three modelling techniques, XGBoost, decision tree and logistic regression, were assessed for their relative performance in terms of precision, sensitivity and specificity.

**Results.** There were 12471 unique patient encounters. Training was done on 10459 encounters and 39 data elements were included. When tested on 2012 encounters, the logistic regression model performed the best (86.7% sensitivity, 71.4% specificity). The model correctly classified 1377 out of 1388 (99.2%) encounters as "appropriate" (do not require ASP intervention). 624 antibiotic use encounters were classified as "inappropriate", of which only 72 were truly inappropriate (positive predictive value for ASP intervention, PPV 11.5%). The low PPV was likely due to inadequate representation of "inappropriate" cases in the training dataset (4.1%). Applying this model would prioritise the number of immediate ASP reviews needed to identify cases for intervention by two-thirds, from 2012 to 624 (Figure 1).

Figure 1. Illustration of AI benefits in ASP



\*ASP reviews all inpatients prescribed with intravenous piperacillin-tazobactam, meropenem, ertapenem, doripenem, imipenem, ciprofloxacin or levofloxacin, for appropriateness of antibiotic choice, dose, duration and route.

**Conclusion.** ASPs can leverage on machine learning capabilities to improve audit efficiency. This can increase ASP's productivity and staff's job satisfaction as they are freed up to perform other work.

**Disclosures.** All Authors: No reported disclosures

### 105. Fluoroquinolone Stewardship at a Community Health-System: A Decade in Review




Matthew Song, PharmD, BCIDP<sup>1</sup>; Ashley Wilde, PharmD, BCPS-AQ ID<sup>1</sup>; Ashley Wilde, PharmD, BCPS-AQ ID<sup>1</sup>; Sarah E. Moore, PharmD, BCIDP<sup>1</sup>; Brian C. Bohn, PharmD, BCIDP<sup>1</sup>; Paul S. Schulz, MD<sup>1</sup>; <sup>1</sup>Norton Healthcare, Louisville, Kentucky

**Session:** P-07. Antimicrobial Stewardship: Program Development and Implementation

**Background.** Fluoroquinolone stewardship is a common target for antimicrobial stewardship programs seeking to maintain or improve fluoroquinolone susceptibility rates. Additional benefits include reducing *C. difficile* infection rates, drug toxicities, and resistance to other antimicrobials as fluoroquinolones can co-select for resistance. The Norton Healthcare antimicrobial stewardship program was founded in 2011 and provides services at 4 adult hospitals with ~1600 beds. Main fluoroquinolone stewardship activities have included provider education, prospective audit and feedback, and guideline and order-set development. The purpose of this study was to describe the resistance and usage rates of fluoroquinolones over time.

**Methods.** This was a descriptive study examining individual adult hospital antibiograms from 2010 to 2020. Levofloxacin susceptibility rates to *E. coli* and *P. aeruginosa* were collated from annual antibiograms between 2010 and 2020 for outpatients and each adult hospital. Adult hospital resistance rates were aggregated and weighted accordingly to number of isolates per hospital per year. Additionally, levofloxacin and ciprofloxacin inpatient days of therapy (DOT) was collected since 2016 when DOT was first readily retrievable and was normalized per 1000 patient days to compare between different time points.

**Results.** Outpatient levofloxacin likelihood of activity against *P. aeruginosa* improved from 81% to 91%. Outpatient levofloxacin likelihood of activity against *E. coli* remained stable between 84 – 86% (Figure 1). Adult inpatient fluoroquinolone usage decreased by approximately 75% from 83.5 to 21.37 DOT/1000 patients since 2016 (Figure 2). Adult inpatient levofloxacin likelihood of activity against *P. aeruginosa* improved from 53% to 83%. Adult inpatient levofloxacin likelihood of activity against *E. coli* improved from 65% to 75% (Figure 3).



**Conclusion.** The Norton Healthcare antimicrobial stewardship program has been effective in reducing unnecessary fluoroquinolone usage and improving inpatient fluoroquinolone susceptibility rates. Future studies should examine opportunities to translate successes to the outpatient phase of care.

**Disclosures.** Ashley Wilde, PharmD, BCPS-AQ ID, Nothing to disclose Paul S. Schulz, MD, Gilead (Consultant, Speaker's Bureau) Merck (Consultant, Speaker's Bureau)

### 106. Pandemic Pinch: The Impact of COVID Response on Antimicrobial Stewardship Program (ASP) Resource Allocation

Elizabeth Dodds Ashley, PharmD, MHS<sup>1</sup>; April Dyer, PharmD, MBA<sup>1</sup>; Travis M. Jones, PharmD<sup>1</sup>; Melissa D. Johnson, PharmD, MHS<sup>1</sup>; Angelina Davis, PharmD, MS<sup>2</sup>; Katherine R. Foy, RN<sup>2</sup>; Alicia Nelson, MPH<sup>3</sup>; Sonali D. Advani, MBBS, MPH<sup>4</sup>; Sonali D. Advani, MBBS, MPH<sup>4</sup>; Andrea Cromer, BSN, MT, MPH, CIC, CPH<sup>5</sup>; Danielle Doughman, MSPH<sup>6</sup>; Ibukunoluwa Akinboyo, MD<sup>7</sup>; Emily Sickbert-Bennett, PhD, MS<sup>7</sup>; Rebekah W. Moehring, MD, MPH<sup>1</sup>; Deverick J. Anderson, MD, MPH<sup>1</sup>; Steven S. Spire, MD<sup>1</sup>; <sup>1</sup>Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC; <sup>2</sup>Duke University School of Medicine, Durham, North Carolina; <sup>3</sup>Duke University, Durham, NC; <sup>4</sup>Duke University School of Medicine, Duke Infection Control Outreach Network, Durham, NC; <sup>5</sup>Duke Infection Control Outreach Network (DICON), Inman, South Carolina; <sup>6</sup>University of North Carolina Medical Center, Chapel Hill, North Carolina <sup>7</sup>UNC Health Care, Chapel Hill, NC

**Session:** P-07. Antimicrobial Stewardship: Program Development and Implementation

**Background.** The COVID-19 pandemic placed a strain on inpatient clinical and hospital programs due to increased patient volume and rapidly evolving data on best COVID-19 management strategies. However, the impact of the pandemic on ASPs has not been well described.

**Methods.** We performed a cross-sectional electronic survey of stewardship pharmacy and physician leaders in 37 hospitals within the Duke Antimicrobial Stewardship Outreach Network (DASON) (community) and Duke/UNC Health systems (academic) in April-May 2021. The survey included 60 questions related to staffing changes, use of COVID-targeted therapies, related restrictions, and medication shortages.

**Results.** Twenty-seven facilities responded (response rate of 73%). Pharmacy personnel was reduced in 17 (63%) facilities by an average of 16%. Impacted pharmacy personnel included the stewardship lead in 15/17 (88.2%) hospitals. Converting to remote work was rare and only reported in academic institutions (n=2, 7.4%). ASP personnel were reassigned to non-stewardship duties in 12 (44%) hospitals with only half returning to routine ASP work as of May 2021. Respondents estimated that 62% of routine ASP activities were diverted during the time of the pandemic. Non-traditional, pandemic-related ASP activities included managing multiple drug shortages, of which ventilator support medications (91%) were most common affecting patient care at 52% of facilities. Steroid and hydroxychloroquine shortages were less frequent (44% and 22%, respectively). Despite staff reductions, pharmacists often served as primary contact for remdesivir approvals either using a criteria-based checklist at dispensing or as part of a dedicated phone approval team (Figure). Most (77%) hospitals used a criteria-based pharmacist review strategy after remdesivir FDA approval. Restriction processes for other COVID-19 therapies such as tocilizumab, hydroxychloroquine, and ivermectin were reported in 64% of hospitals.

Remdesivir Allocation Strategy

